Hester Biosciences on Friday reported more than two-fold jump in net profit to ₹11 crore for the third quarter ended December 31, 2025.
The company had reported a net profit of ₹4 crore in the third quarter of 2024-25, the company said in a statement.
Revenue from operations of the company rose by 12% to ₹70 crore in the third quarter of the current fiscal, compared to ₹63 crore in the year-ago period, it added.
1 January 2026
Get the latest issue of Outlook Business
The Poultry Healthcare Division delivered 32% growth in the December quarter on improved placements and sustained demand for vaccines.
However, the Animal Healthcare Division recorded a 38% decline in the period under review primarily due to delays in government-led immunisation programmes in the ruminant segment, particularly PPR and Goat Pox.
The company also received marketing and manufacturing licences for the H9N2 Avian Influenza vaccine, marking an important regulatory milestone and further strengthening Hester's poultry vaccine portfolio, the statement said.
